Loading…
A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization
Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study t...
Saved in:
Published in: | Retrovirology 2013-02, Vol.10 (1), p.14-14, Article 14 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193 |
---|---|
cites | cdi_FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193 |
container_end_page | 14 |
container_issue | 1 |
container_start_page | 14 |
container_title | Retrovirology |
container_volume | 10 |
creator | Wang, Wenbo Nie, Jianhui Prochnow, Courtney Truong, Carolyn Jia, Zheng Wang, Suting Chen, Xiaojiang S Wang, Youchun |
description | Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral infectivity, virion production, and antibody-mediated neutralization.
Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated neutralization phenotype. Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost infectivity. PNGS mutations located on V4/C4/V5 (except N392 on V4), were shown to increase viral infectivity. Furthermore, FE is much more dependent on specific glycans than clade B Env YU-2. On neutralization effect, PNGS mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41. Generally, mutations on V4/V5 loops, C2/C3/C4 regions and gp41 reduced the neutralization sensitivity to PG16. However, mutation of N289 (C2) made the virus more sensitive to both PG9 and PG16. Furthermore, we showed that mutations at N142 (V1), N355 (C3) and N463 (V5) conferred resistance to neutralization by anti-gp41 MAbs. We used the available structural information of HIV Env and homology modeling to provide a structural basis for the observed biological effects of these mutations.
This report provides the first systematic experimental account of the biological role of the entire PNGS on an HIV-1 Env, which should provide valuable insights for understanding the function of Env in HIV infection cycle and for developing future anti-HIV strategies. |
doi_str_mv | 10.1186/1742-4690-10-14 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3648360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534690417</galeid><sourcerecordid>A534690417</sourcerecordid><originalsourceid>FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193</originalsourceid><addsrcrecordid>eNqNks9rFTEQx4MotlbP3iTgxcu2ySbZTS7Co6gtFL2o15CXzL6m7CbPTfbBFvzfzb7WZyseJD-Z-cyXyWQQek3JKaWyOaMtryveKFLRMvkTdHywPH1wP0IvUrohhFFJ5HN0VDMmeS34Mfq5wmlOGQaTvcUpT27GscP5GvDnatPPNqa5L74YcPIZ0uK8uPxeUQxhB33cAt6OMYMPuCA-dGCz3_k8YxNcWdmvo5urAZw3GRwOMOXR9P52r_kSPetMn-DV_XmCvn388PX8orr68unyfHVVWSHbXIFhjNat7BpllQEuym4Zc5ySpgBc2paXt3WSlnc5JURHrQPujFwrIaliJ-j9ne52WpdULIQlCb0d_WDGWUfj9WNP8Nd6E3eaNVyyhhSBd_cCY_wxQcp68MlC35sAcUqaMlHXSjS0-Q-Uq5ZwRRfVt3-hN3EaQ6lEodqWCylp-4famB50KXEsKdpFVK8EW76X76nTf1BlOBi8jQE6X-yPAs7uAuwYUxqhO5SDEr00l17aRy_43sJLxJuHVTzwv7uJ_QLz2slY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1377458817</pqid></control><display><type>article</type><title>A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization</title><source>NCBI_PubMed Central(免费)</source><source>Publicly Available Content Database</source><creator>Wang, Wenbo ; Nie, Jianhui ; Prochnow, Courtney ; Truong, Carolyn ; Jia, Zheng ; Wang, Suting ; Chen, Xiaojiang S ; Wang, Youchun</creator><creatorcontrib>Wang, Wenbo ; Nie, Jianhui ; Prochnow, Courtney ; Truong, Carolyn ; Jia, Zheng ; Wang, Suting ; Chen, Xiaojiang S ; Wang, Youchun</creatorcontrib><description>Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral infectivity, virion production, and antibody-mediated neutralization.
Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated neutralization phenotype. Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost infectivity. PNGS mutations located on V4/C4/V5 (except N392 on V4), were shown to increase viral infectivity. Furthermore, FE is much more dependent on specific glycans than clade B Env YU-2. On neutralization effect, PNGS mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41. Generally, mutations on V4/V5 loops, C2/C3/C4 regions and gp41 reduced the neutralization sensitivity to PG16. However, mutation of N289 (C2) made the virus more sensitive to both PG9 and PG16. Furthermore, we showed that mutations at N142 (V1), N355 (C3) and N463 (V5) conferred resistance to neutralization by anti-gp41 MAbs. We used the available structural information of HIV Env and homology modeling to provide a structural basis for the observed biological effects of these mutations.
This report provides the first systematic experimental account of the biological role of the entire PNGS on an HIV-1 Env, which should provide valuable insights for understanding the function of Env in HIV infection cycle and for developing future anti-HIV strategies.</description><identifier>ISSN: 1742-4690</identifier><identifier>EISSN: 1742-4690</identifier><identifier>DOI: 10.1186/1742-4690-10-14</identifier><identifier>PMID: 23384254</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Analysis ; Antibodies, Neutralizing - immunology ; env Gene Products, Human Immunodeficiency Virus - chemistry ; env Gene Products, Human Immunodeficiency Virus - genetics ; env Gene Products, Human Immunodeficiency Virus - immunology ; Experiments ; Glycosylation ; Health aspects ; HIV (Viruses) ; HIV Antibodies - immunology ; HIV infection ; HIV-1 - chemistry ; HIV-1 - genetics ; HIV-1 - immunology ; HIV-1 - physiology ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Humans ; Infection ; Monoclonal antibodies ; Mutation ; Neutralization Tests ; Polysaccharides ; Proteins ; Virus diseases ; Virus Replication</subject><ispartof>Retrovirology, 2013-02, Vol.10 (1), p.14-14, Article 14</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Wang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Wang et al; licensee BioMed Central Ltd. 2013 Wang et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193</citedby><cites>FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648360/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1377458817?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23384254$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Wenbo</creatorcontrib><creatorcontrib>Nie, Jianhui</creatorcontrib><creatorcontrib>Prochnow, Courtney</creatorcontrib><creatorcontrib>Truong, Carolyn</creatorcontrib><creatorcontrib>Jia, Zheng</creatorcontrib><creatorcontrib>Wang, Suting</creatorcontrib><creatorcontrib>Chen, Xiaojiang S</creatorcontrib><creatorcontrib>Wang, Youchun</creatorcontrib><title>A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization</title><title>Retrovirology</title><addtitle>Retrovirology</addtitle><description>Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral infectivity, virion production, and antibody-mediated neutralization.
Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated neutralization phenotype. Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost infectivity. PNGS mutations located on V4/C4/V5 (except N392 on V4), were shown to increase viral infectivity. Furthermore, FE is much more dependent on specific glycans than clade B Env YU-2. On neutralization effect, PNGS mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41. Generally, mutations on V4/V5 loops, C2/C3/C4 regions and gp41 reduced the neutralization sensitivity to PG16. However, mutation of N289 (C2) made the virus more sensitive to both PG9 and PG16. Furthermore, we showed that mutations at N142 (V1), N355 (C3) and N463 (V5) conferred resistance to neutralization by anti-gp41 MAbs. We used the available structural information of HIV Env and homology modeling to provide a structural basis for the observed biological effects of these mutations.
This report provides the first systematic experimental account of the biological role of the entire PNGS on an HIV-1 Env, which should provide valuable insights for understanding the function of Env in HIV infection cycle and for developing future anti-HIV strategies.</description><subject>Analysis</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>env Gene Products, Human Immunodeficiency Virus - chemistry</subject><subject>env Gene Products, Human Immunodeficiency Virus - genetics</subject><subject>env Gene Products, Human Immunodeficiency Virus - immunology</subject><subject>Experiments</subject><subject>Glycosylation</subject><subject>Health aspects</subject><subject>HIV (Viruses)</subject><subject>HIV Antibodies - immunology</subject><subject>HIV infection</subject><subject>HIV-1 - chemistry</subject><subject>HIV-1 - genetics</subject><subject>HIV-1 - immunology</subject><subject>HIV-1 - physiology</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>Infection</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Neutralization Tests</subject><subject>Polysaccharides</subject><subject>Proteins</subject><subject>Virus diseases</subject><subject>Virus Replication</subject><issn>1742-4690</issn><issn>1742-4690</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNks9rFTEQx4MotlbP3iTgxcu2ySbZTS7Co6gtFL2o15CXzL6m7CbPTfbBFvzfzb7WZyseJD-Z-cyXyWQQek3JKaWyOaMtryveKFLRMvkTdHywPH1wP0IvUrohhFFJ5HN0VDMmeS34Mfq5wmlOGQaTvcUpT27GscP5GvDnatPPNqa5L74YcPIZ0uK8uPxeUQxhB33cAt6OMYMPuCA-dGCz3_k8YxNcWdmvo5urAZw3GRwOMOXR9P52r_kSPetMn-DV_XmCvn388PX8orr68unyfHVVWSHbXIFhjNat7BpllQEuym4Zc5ySpgBc2paXt3WSlnc5JURHrQPujFwrIaliJ-j9ne52WpdULIQlCb0d_WDGWUfj9WNP8Nd6E3eaNVyyhhSBd_cCY_wxQcp68MlC35sAcUqaMlHXSjS0-Q-Uq5ZwRRfVt3-hN3EaQ6lEodqWCylp-4famB50KXEsKdpFVK8EW76X76nTf1BlOBi8jQE6X-yPAs7uAuwYUxqhO5SDEr00l17aRy_43sJLxJuHVTzwv7uJ_QLz2slY</recordid><startdate>20130206</startdate><enddate>20130206</enddate><creator>Wang, Wenbo</creator><creator>Nie, Jianhui</creator><creator>Prochnow, Courtney</creator><creator>Truong, Carolyn</creator><creator>Jia, Zheng</creator><creator>Wang, Suting</creator><creator>Chen, Xiaojiang S</creator><creator>Wang, Youchun</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130206</creationdate><title>A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization</title><author>Wang, Wenbo ; Nie, Jianhui ; Prochnow, Courtney ; Truong, Carolyn ; Jia, Zheng ; Wang, Suting ; Chen, Xiaojiang S ; Wang, Youchun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Analysis</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>env Gene Products, Human Immunodeficiency Virus - chemistry</topic><topic>env Gene Products, Human Immunodeficiency Virus - genetics</topic><topic>env Gene Products, Human Immunodeficiency Virus - immunology</topic><topic>Experiments</topic><topic>Glycosylation</topic><topic>Health aspects</topic><topic>HIV (Viruses)</topic><topic>HIV Antibodies - immunology</topic><topic>HIV infection</topic><topic>HIV-1 - chemistry</topic><topic>HIV-1 - genetics</topic><topic>HIV-1 - immunology</topic><topic>HIV-1 - physiology</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>Infection</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Neutralization Tests</topic><topic>Polysaccharides</topic><topic>Proteins</topic><topic>Virus diseases</topic><topic>Virus Replication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Wenbo</creatorcontrib><creatorcontrib>Nie, Jianhui</creatorcontrib><creatorcontrib>Prochnow, Courtney</creatorcontrib><creatorcontrib>Truong, Carolyn</creatorcontrib><creatorcontrib>Jia, Zheng</creatorcontrib><creatorcontrib>Wang, Suting</creatorcontrib><creatorcontrib>Chen, Xiaojiang S</creatorcontrib><creatorcontrib>Wang, Youchun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Retrovirology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Wenbo</au><au>Nie, Jianhui</au><au>Prochnow, Courtney</au><au>Truong, Carolyn</au><au>Jia, Zheng</au><au>Wang, Suting</au><au>Chen, Xiaojiang S</au><au>Wang, Youchun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization</atitle><jtitle>Retrovirology</jtitle><addtitle>Retrovirology</addtitle><date>2013-02-06</date><risdate>2013</risdate><volume>10</volume><issue>1</issue><spage>14</spage><epage>14</epage><pages>14-14</pages><artnum>14</artnum><issn>1742-4690</issn><eissn>1742-4690</eissn><abstract>Glycans on the human immunodeficiency virus (HIV) envelope glycoprotein (Env) play an important role in viral infection and evasion of neutralization by antibodies. In this study, all 25 potential N-linked glycosylation sites (PNGS) on the HIV-1 CRF07_BC Env, FE, were mutated individually to study the effect of their removal on viral infectivity, virion production, and antibody-mediated neutralization.
Removal of specific N-glycosylation sites has a significant effect on viral infectivity and antibody-mediated neutralization phenotype. Six of these glycosylation mutants located on the V1/V2 and C1/C2 domains lost infectivity. PNGS mutations located on V4/C4/V5 (except N392 on V4), were shown to increase viral infectivity. Furthermore, FE is much more dependent on specific glycans than clade B Env YU-2. On neutralization effect, PNGS mutations at N197 (C2), N301 (V3), N442 (C4) and N625 (gp41) rendered the virus more susceptible to neutralization by the monoclonal antibodies (MAbs) that recognize the CD4 binding site or gp41. Generally, mutations on V4/V5 loops, C2/C3/C4 regions and gp41 reduced the neutralization sensitivity to PG16. However, mutation of N289 (C2) made the virus more sensitive to both PG9 and PG16. Furthermore, we showed that mutations at N142 (V1), N355 (C3) and N463 (V5) conferred resistance to neutralization by anti-gp41 MAbs. We used the available structural information of HIV Env and homology modeling to provide a structural basis for the observed biological effects of these mutations.
This report provides the first systematic experimental account of the biological role of the entire PNGS on an HIV-1 Env, which should provide valuable insights for understanding the function of Env in HIV infection cycle and for developing future anti-HIV strategies.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23384254</pmid><doi>10.1186/1742-4690-10-14</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1742-4690 |
ispartof | Retrovirology, 2013-02, Vol.10 (1), p.14-14, Article 14 |
issn | 1742-4690 1742-4690 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3648360 |
source | NCBI_PubMed Central(免费); Publicly Available Content Database |
subjects | Analysis Antibodies, Neutralizing - immunology env Gene Products, Human Immunodeficiency Virus - chemistry env Gene Products, Human Immunodeficiency Virus - genetics env Gene Products, Human Immunodeficiency Virus - immunology Experiments Glycosylation Health aspects HIV (Viruses) HIV Antibodies - immunology HIV infection HIV-1 - chemistry HIV-1 - genetics HIV-1 - immunology HIV-1 - physiology Human immunodeficiency virus Human immunodeficiency virus 1 Humans Infection Monoclonal antibodies Mutation Neutralization Tests Polysaccharides Proteins Virus diseases Virus Replication |
title | A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A36%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20systematic%20study%20of%20the%20N-glycosylation%20sites%20of%20HIV-1%20envelope%20protein%20on%20infectivity%20and%20antibody-mediated%20neutralization&rft.jtitle=Retrovirology&rft.au=Wang,%20Wenbo&rft.date=2013-02-06&rft.volume=10&rft.issue=1&rft.spage=14&rft.epage=14&rft.pages=14-14&rft.artnum=14&rft.issn=1742-4690&rft.eissn=1742-4690&rft_id=info:doi/10.1186/1742-4690-10-14&rft_dat=%3Cgale_pubme%3EA534690417%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c587t-ea331278f69c9ae45c9ac33d410658748c74031f81338d955f1cde4da8b958193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1377458817&rft_id=info:pmid/23384254&rft_galeid=A534690417&rfr_iscdi=true |